This led to the recommendation of mTOR inhibitors for the patient, as loss of TSC1/2 through mutations or deletions have been associated with everolimus response in multiple cancer types including bladder cancer [53], hepatocellular carcinoma [54], subependymal giant cell astrocytoma (SEGA), and renal angiomyolipoma [55]. This evidence concerns the gene MTOR and cancer.